Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome

• Hoofdauteurs: Michael C. Snabes, M.D., Ph.D (Auteur), Juki Ng, Pharm.D., Ph.D (Auteur), Hong Li, Ph.D (Auteur), Izna Ali, Pharm.D., Ph.D (Auteur), Mohamad Shebley, Ph.D (Auteur), William D. Schlaff, M.D (Auteur)
• Formaat: Boek
• Gepubliceerd in: Elsevier, 2023-06-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Objective: Evaluate the efficacy and safety of elagolix, a GnRH antagonist, to treat polycystic ovarian syndrome (PCOS). Design: A phase 2, multicenter, double-blind, randomized, placebo-controlled trial. Setting: Outpatient and academic medical centers. Patient(s): One hundred fourteen women with P...